Actively Recruiting

All Genders
ID03607565

The Association Between a New Parameter Derived From DSA and Outcomes in Cerebral Ischemia

Led by Xi'an No.3 Hospital · Updated on 2023-09-01

30000

Participants Needed

1

Research Sites

521 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Ischemic cerebrovascular disease is a leading cause of death and disability worldwide. This study investigates a new parameter derived from Digital Subtraction Angiography (DSA) to evaluate cerebral blood flow and predict outcomes in patients with cerebral ischemia, specifically acute stroke with large vessel occlusion. Researchers aim to understand the relationship between this new DSA-based perfusion parameter and patient outcomes measured by the modified Rankin Scale. The study is observational and analyzes images from patients who have undergone DSA. Participants are classified based on their cerebral perfusion levels into good, middle, or poor perfusion groups using this new parameter. The study does not involve interventions but focuses on evaluating and comparing outcomes among these groups. Participants' DSA images and follow-up data on their clinical outcomes, collected between 3 months and 2 years after the procedure, will be analyzed. The main outcome measured is the difference in recovery and disability levels between patients with good and poor perfusion. Additional comparisons between good and middle perfusion groups will also be reviewed. The study is conducted by Xi'an No.3 Hospital and will continue until July 2038.

CONDITIONS

Brief Title

A New Parameter Derived From DSA to Evaluate Cerebral Perfusion

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of cerebral ischemia
  • Patients who have undergone Digital Subtraction Angiography (DSA)
Not Eligible

You will not qualify if you...

  • Presence of cerebral hemorrhage

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Single day

Participants undergo Digital Subtraction Angiography (DSA) to evaluate cerebral blood vessels and assess cerebral perfusion.

1 visit (in-person)

Long-term Monitoring

Duration - 3 months to 2 years

Participants are followed up to assess outcomes related to cerebral perfusion over time.

Periodic follow-up visits depending on clinical schedule

Trial Site Locations

Total: 1 location

1

Xi'an No.3 Hospital

Xi'an, Shaanxi, China, 710018

Actively Recruiting

Loading map...

Research Team

T

Tian Ye, doctor

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Similar Trials

Autologous Mitochondrial Transplant for Cerebral Ischemia Du...

Cerebral Ischemia

Actively Recruiting

1 location

Effect of Xenon on Brain Injury, Neurological Outcome and Su...

Subarachnoid Hemorrhage, Aneurysmal

Actively Recruiting

7 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here